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Abstract : In this study， we examined the features of patients with advanc巴dunresectable 
squamous cel carcinoma of the thoracic esophagus in our hospital and validated our strategy of 
intensive treatment. The average age of our patients was higher than thos巴 reportedby other 
facilities and our elderly patients had various kinds of complications. We basically performed 
either chemoradiation (CRT) or radiation (RT) therapy for these patients with unresectable 
esophageal cancer. Median survival time of the intensively treated patients with CRT / RT 
was almost twice longer than those with only best supportive care. An improved food intake 
was noted in two-thir司dsof our patients after CRT / RT because of tumor shrinkage. For 
the less collapsing ratio of CRT， we chose concurrent CRT with low】dosecisplatin (CDDP) 
(48) 古川政統他24~[
plus continuous infusion of 5-fluorouracil (LDFP) especially to elderly patients. Actually， in 
our hospital， the incidence of hematotoxicity by LDFP was distinctly lower compared with 
the standard-dose CDDP plus continuous infusion of 5-fluorouracil (SDFP). Additionally， 
new combination chemoradiotherapy with cisdiammine-glycolate platinum (Nedaplatin) 
and 5-fluorouracil was given to patients with advanc巴d巴sophagealcancer and other organ 
metastasis. N edaplatin has be巴nknown to be less toxic for kidney and digestive organs and to 
show much stronger antitumor activity compared to CDDP in patients with esophageal cancer. 
Our overall CRT / RT outcome should be acceptable， iftaking patients' ages and their various 
complications into consideration. We recognized the necessity of making an appropriate medical 
decision in each elderly patient receiving intensive treatment against unresectable advanced 
esophageal cancer and of managing adverse effects of CRT / RT promptly for attaining good 
prognosis and high quality of life. 
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The combined modality therapy consisted of 
nedaplatin (CDGP). 60 mg/m2 intravenously. on the 
sixth and seventh day of weeks 1. 7. 12. The patients 
were given a continuous infusion of 5-fluorouracil， 
700 mg/m2. for the first 5 days of weeks 1，
7， 12. From the supraclavicular fossae to the 
esophagogastric junction， radiation was delivered at 
36 Gy in 20 fractions over 4 weeks starting on day 
10. followed by 27 Gy in 15 fractions over 3 weeks 
starting on day 52 
を基本とした また，合併症により化学療法を安全
に行えない一部の症例では放射線療法 (以下 RT)を
選択した. Stage IVa症例には CRTを実施し， Stage 
IVb症例に対しては1)標準量 FP療法と放射線照射





上対症療法を基軸とした BestSupportive Care (以
下BSC)を行った
放射線照射に関しては基本照射量を 60Gyとして，












治 療 成 績
上記の治療アルゴリズムに沿った当科の治療成績を
各 Stage別に分類して Table3に示した Stage1全
6症例のうち l例には CRT、5例には RTを行い両群
ともに 100%の完全寛解 (CR) 率を得たが， RT治
療群では経過観察中に 40%にあたる 2例で局所再発
を認め，うち 1例が腫蕩死した StageI全9症例の




増悪に伴う死亡例を認めた Stage II は全 6症例と
もCRTを行い，奏功率 100%と良好であったが， CR 
維持率は 17%にとどまり， 2例 (33%)が腫蕩死した
Stage IVaはCRT5例，RT3初U，BSC4例であ った.


















5例 40% 80% 



































群の中央生存期間はそれぞれ 176日と 70日であり. 2 
倍以上の開きがあった (Tabl巴 4).多臓器転移を伴う




























治療方法 症例数 早期合併症(Grade3以上) 晩期合併症(Grade3以上)





























日であり. 5 cm未満の症例の 366日と比較して約半






量 FP~ CRT治療群と交替療法 CRT治療群の 30%



















今回の当科の食道がん症例 44例のうち 40例 (91%)
は扇平上皮癌であり，残り 4例の内訳は小細胞癌 2例，















































である大動脈穿破症例を 2例に認めた I例は Stag巴
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